Amgen investors await weight-loss drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
Amgen (AMGN) PT Lowered to $328 at RBC Capital
May 3, 2024 6:35 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Amgen (NASDAQ: AMGN) to $328.00 (from $332.00) while maintaining a Outperform rating.
The analyst comments "GLP-1/GIPR, MariTides stated success on the ph.II interim data look internally takes the cake on the call,... More
